PTO/SB/96 (08-00)


FRADE!

.0	DER 37 CFR 3.73(b)
Applicant/Patent Owner: Dale B. Schenk	
	Filed/Jesus Date: May 26, 2000
Application No./Patent No.: 09/580,018	Filed/Issue Date: May 26, 2000
Entitled: PREVENTION AND TREATMENT OF AMYLOID	OGENIC DISEASE
Neuralab Limited , a corp	Oration Assignee, e.g., corporation, partnership, university, government agency, etc.)
,	Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:	
1. the assignee of the entire right, title, and inter	est; or
an assignee of an undivided part interest	
in the patent application/patent identified above by virtue of	f either:
 An assignment from the inventor(s) of the patent ap recorded in the Patent and Trademark Office at Ree attached. 	plication/patent identified above. The assignment was i, or for which a copy thereof is
OR	
B. A chain of title from the inventor(s), of the patent ap shown below:	plication/patent identified above, to the current assignee as
From: Dale B. Schenk, Frederique Bard, and Theodore Yednock	
The document was recorded in the United Stat Reel 011230, Frame 0598, or for which a copy	
 From: <u>Elan Pharmaceuticals, Inc.</u> The document was recorded in the United Stat Reel <u>011230</u>, Frame <u>0585</u>, or for which a copy 	
3. From:	To :
The document was recorded in the United Stat	
Reel, Frame, or for which a copy	thereof is attached.
☐ Additional documents in the chain of title are list	sted on a supplemental sheet.
Copies of assignments or other documents in the chain NOTE: A separate copy (i.e., the original assignment of must be submitted to Assignment Division in accordant recorded in the records of the USPTO. See MPEP 302	document or a true copy of the original document) ce with 37 CFR Part 3, if the assignment is to be
The undersigned (whose title is supplied below) is empow	ered to sign this statement on behalf of the assignee.
September / , 2001	160 Thank
Date	Signature
	Kevin Insley ``´ Typed or printed name
	Typed of printed flame

Eurdenmour Statement. This form is estimated to take 0.27 subside complete. Time will vary depending open the needs of their dividual dase. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

17-6 Procident





PTO/SB/81 (02-01)
Approved for use through 10/31/2002 OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY OR **AUTHORIZATION OF AGENT**

ider the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.				
WYNYOU	Application Number	09/580,018		
POWER OF ATTORNEY OR AUTHORIZATION OF AGENT	Filing Date	May 26, 2000		
	First Named Inventor	Dale B. Schenk		
	Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE		
	Group Art Unit	1641		
	Examiner Name	Unassigned.		
	Attorney Docket Number	15270J-004760US		

I hereby a	ppoint:			Place Customer		
☐ Practition	oners at Customer Numb	er	>	Number Bar Code Label here		
☑ Practiti	oner(s) named below:					
į	Name		Regist	ration Number		
	Nina N	. Ashton		37,273		
	Jean M. Duvall			32,731		
	Lisabeth F. Murphy			31,547		
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.						
The abo	nge the correspondence overmentioned Customer oners at Customer Number	Number.	entified application to	-		
Firm or Individu	ial Name					
Address						
Address						
City			State	ZIP		
Country						
Telephone			Fax			
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
SIGNATURE of Applicant or Assignee of Record						
Name	Neuralab Limited, by:	Kevin Insley, Vice Presi	dent			

NOTE. Signatures of all the inventors of assignees of record of the entire offerest of their representative is large required. Submit multiple forms if more than one signature is required, see below*.

Please type (plus sign (+) inside this box

PTO/SB/81 (02-01)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
Group Art Unit	1641
Examiner Name	Unassigned.
Attorney Docket Number	15270J-004760US

I hereby appoint:					Place Customer	¬
☑ Practitioners at 0	Customer Number	20350	-		Number Bar Code	
<i>OR</i> ☐ Practitioner(s) na	arned below:				Label here	
Fractitioner(s) in	Nam-	e		Registrati	on Number	
		Name				
						
			-			
		4 . 4	:	d above and to	transact all	
as my/our attorney(s business in the Unite	e) or agent(s) to pros ed States Patent and ————————————————————————————————————	secute the application d Trademark Office o	onnected	therewith.	transact all	·
Please change the c	orrespondence add	ress for the above-ide	entified ap	oplication to:		
The above-menti	oned Customer Nur	mber.		_		
OR		-			•	
Practitioners at C	Customer Number	L				
Firm or Individual Name						
Address						
Address						
City			State		ZIP	
Country						
Telephone			Fax			
I am the:						
☐ Applicant/Inve	ntor.					
Assignee of re	cord of the entire in	terest. See 37 CFR 3	3.71.			:
Statement und	er 37 CFR 3.73(b) is	s enclosed. (Form PT	O/SB/96)	<u>. </u>		
SIGNATURE of Applicant or Assignee of Record						
Name Neura	lab Limited, by Ke	vin Insley, Vice Presid	dent			
Signature	Signature // M. T. Tarm.				1 000	
and the state of the						
outmit multiple forms it in one than one signature is the purebol is in looking.						

Burden Hour Statement. This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Fatents Washington Du 1/2/31 4/3167768 . 1



